<!DOCTYPE html>
<html lang="en-US">
<meta charset="UTF-8">

<title>OB/GYN Referenced</title>
<meta name="theme-color" content="#000000" />
<meta name="description" content="Genital Herpes">
<meta name="viewport" content="width=device-width, initial-scale=1">
<link rel="shortcut icon" href="favicon.ico" type="image/x-icon">
<link rel="manifest" href="manifest.json">
<link rel="stylesheet" href="css/w3.css">
<link rel="stylesheet" href="css/hg.css">


<body onload="SetUpPage()">

    <header id="MyHeader" class="hg-NavBar">
        <a id="bkbtn" class="hg-BackButton" href="javascript:void(0)" onclick="goBack()"></a>
        <a id="hmbrgbtn" class="hg-HamBtn" href="javascript:void(0)" onclick="SideBarOpen()"></a>
        <span id="titbar" class="hg-NavBarTitle"></span>
    </header>

    <nav class="hg-SideBar" id="mySidebar"></nav>

    <div class="hg-OverLay  " onclick="SideBarClose()" title="close side menu" id="myOverlay"></div>

    <div class="hg-Content">

        <main class="hg-InfoContent">
            <h1 class="hg-h1PageTitle">Genital Herpes</h1>

            <h2 class="hg-h2SectionTitle">General</h2>

            <section class="accordian">
                <button onclick="AccToggle('hsvgeninc')" class="hg-accBtn">Incidence USA:<span id="hsvgeninc_c"
                        class="hg-NavLinkChevron"></span></button>
                <div id="hsvgeninc" class="hg-accDivMain">
                    <ul class=hg-accUl>
                        <li>~21% women HSV-2 seropositive (would be higher if included genital
                            HSV-1).<sup>1</sup></li>
                        <li>Only 5–15% patients recognize being infected.<sup>1</sup></li>
                    </ul>
                </div>
            </section>

            <section class="accordian">
                <button onclick="AccToggle('genhsvdef')" class="hg-accBtn">3 episode defintions:<span id="genhsvdef_c"
                        class="hg-NavLinkChevron"></span></button>
                <div id="genhsvdef" class="hg-accDivMain">
                    <ul class=hg-accUl>
                        <li>Primary first-episode infection:
                            <ul>
                                <li>HSV-1 or HSV-2 in lesions and no antibodies to either viral type in
                                    serum.<sup>1</sup></li>
                            </ul>
                        </li>
                        <li>Nonprimary first-episode:
                            <ul>
                                <li>One viral type in lesions and antibodies to the other viral type in
                                    serum<sup>1</sup></li>
                            </ul>
                        </li>
                        <li>Recurrent infection (reactivation of viral replication):
                            <ul>
                                <li>HSV-1 or HSV-2 in lesions and antibodies to the same viral type in
                                    serum.<sup>1</sup>
                                    <ul>
                                        <li>Recurrent ulcerations.<sup>1</sup></li>
                                        <li class="hg-accOr" />
                                        <li>Subclinical asymptomatic shedding.<sup>1</sup></li>
                                    </ul>
                                </li>
                            </ul>
                        </li>
                    </ul>
                </div>
            </section>

            <section class="accordian">
                <button onclick="AccToggle('hsvvirut')" class="hg-accBtn">The virus:<span id="hsvvirut_c"
                        class="hg-NavLinkChevron"></span></button>
                <div id="hsvvirut" class="hg-accDivMain">
                    <ul class=hg-accUl>
                        <li>Double-stranded DNA virus:<sup>1</sup>
                            <ul>
                                <li>HSV-1 (Glycoprotein G1 in lipid bilayer envelope):<sup>1</sup>
                                    <ul>
                                        <li>Causes orolabial HSV.<sup>1</sup>
                                        <li>Increasing common cause of genital HSV particularly in young
                                            women.<sup>1</sup>
                                    </ul>
                                </li>
                                <li> HSV-2 (Glycoprotein G2 in lipid bilayer envelope):<sup>1</sup>
                                    <ul>
                                        <li>Uncommon to cause orolabial HSV.<sup>i</sup></li>
                                        <li>Usually just causes genital infection.<sup>1</sup>
                                        <li>Causes most genital HSV.<sup>1</sup>
                                    </ul>
                                </li>
                            </ul>
                        </li>
                    </ul>
                </div>
            </section>




            <section class="accordian">
                <button onclick="AccToggle('timerfeahsv')" class="hg-accBtn">Time frames:<span id="timerfeahsv_c"
                        class="hg-NavLinkChevron"></span></button>
                <div id="timerfeahsv" class="hg-accDivMain">
                    <ul class=hg-accUl>
                        <li>Incubation 2-12 days after acquiring.<sup>1</sup></li>
                        <li>Type-specific antibodies develop in 2–3 weeks and persist indefinitely.<sup>1</sup></li>
                    </ul>
                </div>
            </section>

            <section class="accordian">
                <button onclick="AccToggle('hsvtesttyp')" class="hg-accBtn">2 types of testing:<span id="hsvtesttyp_c"
                        class="hg-NavLinkChevron"></span></button>
                <div id="hsvtesttyp" class="hg-accDivMain">
                    <ul class=hg-accUl>
                        <li>Viral detection methods:<sup>1</sup>
                            <ul>
                                <li>Viral culture:
                                    <ul>
                                        <li>Low sensitivity:
                                            <ul>
                                                <li>80% positive primary lesions.<sup>1</sup></li>
                                                <li>40% positive with recurrent lesions.<sup>1</sup></li>
                                            </ul>
                                        </li>
                                    </ul>
                                </li>
                            </ul>
                            <ul>
                                <li>Polymerase chain reaction detection HSV antigens:
                                    <ul>
                                        <li>3-5 more sensitive than culture.<sup>1</sup></li>
                                    </ul>
                                </li>
                            </ul>
                        </li>
                        <li>Antibody detection methods:<sup>1</sup>
                        <ul>
                            <li>HSV-2 antibodies:
                                <ul>
                                    <li>Genital HSV-2 infection <sup>1</sup></li>
                                </ul>
                            </li>
                            <li>HSV-1 antibodies:
                                <ul>
                                    <li>Orolabial HSV-1 infection or genital HSV-1 infection.<sup>1</sup></li>
                                </ul>
                            </li>
                        </ul>
                        </li>
                    </ul>
                </div>
            </section>


            <h2 class="hg-h2SectionTitle">Pregnancy</h2>

            <section class="accordian">
                <button onclick="AccToggle('genhsvnewbe')" class="hg-accBtn">New 5/2020:<span id="genhsvnewbe_c"
                        class="hg-NavLinkChevron"></span></button>
                <div id="genhsvnewbe" class="hg-accDivMain">
                    <ul class=hg-accUl>
                        <li>Consider offering c-section if primary or nonprimary first-episode in 3rd trimester
                            secondary to possibility of prolonged viral shedding.<sup>1</sup></li>
                        <li>Consider continuing treatment until delivery if primary or nonprimary first-episode in 3rd
                            trimester.<sup>1</sup></li>
                    </ul>
                </div>
            </section>


            <section class="accordian">
                <button onclick="AccToggle('newhsvpregf')" class="hg-accBtn">New infections in pregnancy:<span
                        id="newhsvpregf_c" class="hg-NavLinkChevron"></span></button>
                <div id="newhsvpregf" class="hg-accDivMain">
                    <ul class=hg-accUl>
                        <li>~10% of HSV-2 seronegative wome are at risk secondary to HSV-2 seropositive
                            partners.<sup>1</sup></li>
                        <li>~2% seronegative women acquire HSV-1 or HSV-2 during pregnancy.<sup>1</sup></li>
                        <li>Most new infections are asymptomatic.<sup>1</sup></li>
                        <li>1/3 new infections occur in each trimester.<sup>1</sup></li>
                        <li>15% first-episode infections in pregnancy are recurrent infections.<sup>1</sup></li>
                    </ul>
                </div>
            </section>

            <section class="accordian">
                <button onclick="AccToggle('pregpercenthsv')" class="hg-accBtn">Recurrent infections in pregnancy:<span
                        id="pregpercenthsv_c" class="hg-NavLinkChevron"></span></button>
                <div id="pregpercenthsv" class="hg-accDivMain">
                    <ul class=hg-accUl>
                        <li>~75% have at least one recurrence in pregnancy.<sup>1</sup></li>
                        <li>~14% have prodromal symptoms or recurrence at delivery.<sup>1</sup></li>


                    </ul>
                </div>
            </section>

            <section class="accordian">
                <button onclick="AccToggle('genhsvneonatdz')" class="hg-accBtn">Neonatal disease:<span
                        id="genhsvneonatdz_c" class="hg-NavLinkChevron"></span></button>
                <div id="genhsvneonatdz" class="hg-accDivMain">
                    <ul class=hg-accUl>
                        <li>~1/3 -1/2 secondary to HSV-1.<sup>1</sup></li>
                        <li>Classified:<sup>1</sup>
                            <ul>
                                <li>25% disseminated disease (mortality 30%).<sup>1</sup></li>
                                <li>30% CNS disease (mortality 4%).<sup>1</sup></li>
                                <li>45% skin, eyes, mouth.<sup>1</sup></li>
                            </ul>
                        </li>
                        <li>~20% survivors long-term neurologic problems.<sup>1</sup></li>
                    </ul>
                </div>
            </section>

            <section class="accordian">
                <button onclick="AccToggle('hsvsupther')" class="hg-accBtn">Treatment:<span id="hsvsupther_c"
                        class="hg-NavLinkChevron"></span></button>
                <div id="hsvsupther" class="hg-accDivMain">
                    <ul class=hg-accUl>
                        <li>Primary or nonprimary first-episode:<sup>1</sup>
                            <ul>
                                <li>Acyclovir:<sup>1</sup>
                                    <ul>
                                        <li>400 mg po TID x 7-10 days.<sup>1</sup></li>
                                        <li>Can extend longer than 10 days if lesions not healed.<sup>1</sup></li>
                                        <li>Option to continue to delivery if occurs in 3rd trimester.<sup>1</sup></li>
                                    </ul>
                                </li>
                                <li>Valacyclovir:<sup>1</sup>
                                    <ul>
                                        <li>1 g po BID x 7-10 days.<sup>1</sup></li>
                                        <li>Can extend longer than 10 days if lesions not healed.<sup>1</sup></li>
                                        <li>Option to continue to delivery if occurs in 3rd trimester.<sup>1</sup></li>
                                    </ul>
                                </li>
                            </ul>
                        </li>
                        <li>Symptomatic recurrent episode:<sup>1</sup>
                            <ul>
                                <li>Acyclovir:<sup>1</sup>
                                    <ul>
                                        <li>400 mg po TID x 5 days or 800 mg po BID x 5d days.<sup>1</sup></li>
                                    </ul>
                                </li>
                                <li>Valacyclovir:<sup>1</sup>
                                    <ul>
                                        <li>500 mg po BID x 3 days or 1 g po daily x 5 days.<sup>1</sup></li>
                                    </ul>
                                </li>
                            </ul>
                        </li>
                        <li>Suppresion:<sup>1</sup>
                            <ul>
                                <li>Acyclovir:<sup>1</sup>
                                    <ul>
                                        <li>400 mg po TID starting at 36 weeks ubtil delivery.<sup>1</sup></li>
                                    </ul>
                                </li>
                                <li>Valacyclovir:<sup>1</sup>
                                    <ul>
                                        <li>500 mg po BID starting at 36 weeks ubtil delivery.<sup>1</sup></li>
                                    </ul>
                                </li>
                            </ul>
                        </li>
                        <li>Severe disease:<sup>1</sup>
                            <ul>
                                <li>Acyclovir<sup>1</sup>
                                    <ul>
                                        <li>5-10 mg/kg IV every 8 hrs x 2-7 days and then po primary regimen to complete
                                            10 days.<sup>1</sup></li>
                                    </ul>
                                </li>
                            </ul>
                        </li>
                    </ul>
                    <!-- <P class="hg-accNote"> xxx<sup>xxx</sup></P> -->
                </div>
            </section>

            <section class="accordian">
                <button onclick="AccToggle('hsvcser')" class="hg-accBtn">C-section:<span id="hsvcser_c"
                        class="hg-NavLinkChevron"></span></button>
                <div id="hsvcser" class="hg-accDivMain">
                    <ul class=hg-accUl>
                        <li>C-section indicated:<sup>xxx</sup>
                            <ul>
                                <li>Active genital lesions or prodromal symptoms.<sup>1</sup></li>
                                <li>Can offer if primary or nonprimary first-episode genital HSV infection in 3rd
                                    trimester secondary to possibility of prolonged viral shedding .<sup>1</sup></li>
                            </ul>
                        </li>
                        <li>C-section not indicated:<sup>xxx</sup>
                            <ul>
                                <li>Nongenital lesions back, thigh, buttock (can cover with occlusive
                                    dressing).<sup>1</sup></li>
                            </ul>
                        </li>
                    </ul>
                    <!--          <P class="hg-accNote"> xxx<sup>xxx</sup></P> -->
                </div>
            </section>

            <section class="accordian">
                <button onclick="AccToggle('hsvppromaxs')" class="hg-accBtn">PPROM:<span id="hsvppromaxs_c"
                        class="hg-NavLinkChevron"></span></button>
                <div id="hsvppromaxs" class="hg-accDivMain">
                    <ul class=hg-accUl>
                        <li>If expectant management antiviral therapy recommended.<sup>1</sup></li>
                    </ul>
                    <P class="hg-accNote"> xxx<sup>xxx</sup></P>
                </div>
            </section>



            <!--  <section class="accordian hg-accSectionRelTopics">
                <button onclick="AccToggle('xxxRelLinks')" class="hg-accBtn">Related topics:<span id="xxxRelLinks_c"
                        class="hg-NavLinkChevron"></span></button>
                <div id="xxxRelLinks" class="hg-accDivMain">
                    <ul class=hg-accUl>
                        <li><a href="xxx.html">XXX</a></li>
                    </ul>
                </div>
            </section> -->

            <section class="accordian hg-accSectionRef">
                <button onclick="AccToggle('genitalhsvRefs')" class="hg-accBtn">References:<span id="genitalhsvRefs_c"
                        class="hg-NavLinkChevron"></span></button>
                <div id="genitalhsvRefs" class="hg-accDivMain">
                    <ol class="hg-accOlRef">
                        <li>Management of genital herpes in pregnancy. ACOG Practice Bulletin No. 220. American College
                            of Obstetricians and Gynecologists. Obstet Gynecol 2020;135:e193–202.</li>
                        <!--   <li>Zacharias N. Perinatal mortality. In: Weisman L, ed. <i>UpToDate.</i> Waltham, Mass.:
                            UpToDate, 2018. https://www.uptodate.com/contents/perinatal-mortality#H1. Accessed Febuary
                            18,2020. </li> -->
                    </ol>
                </div>
            </section>


        </main>

        <div class="hg-AddContent">
            <p class="hg-AddSmall ">AD</p>
            <p class="hg-AddLarge  ">AD</p>
        </div>

    </div>

    <script defer src="script.js"></script>
    <script defer src="script-aux.js"></script>

</body>

</html>